Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Tonix announced operating results for the quarter ended September 30, 2026.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Tonix announced operating results for the quarter ended September 30, 2026
- Detailed financial figures and management commentary are in Exhibit 99.01, the accompanying earnings release
Item EX-99.1 · Exhibit EX-99.1
- TONMYA net sales reached approximately $15.0 million, up 37% quarter-over-quarter, with prescriptions up 28% to 16,375
- Coverage expanded to approximately 166 million lives, or 53% of U.S. covered lives, supporting commercial traction
- Generic challenge from Dr. Reddy’s ANDA creates patent litigation risk to TONMYA’s revenue opportunity
- Cash fell to $162.8 million from $207.6 million, while nine-month operating cash use reached $125.6 million
- Third-quarter net loss widened to $53.3 million as R&D and SG&A increased to $25.8 million and $45.6 million respectively
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.